Takeda veterans, Frazier launch Phathom with $90M to develop GI drug vonoprazan

Marking the partners' second company launch with a Takeda-discovered asset, Frazier Healthcare Partners and the Japanese pharma launched Phathom with rights to gastrointestinal drug vonoprazan. The start-up, which will focus on developing treatments for acid-related disorders, also raised $90 million in a private financing led by the firm and completed a $50 million loan facility with Silicon Valley Bank.